Retirement of Jon Lamb

ADMIN
Thu, Sep 28 2023 12:08 pm





28 September 2023
Retirement of Jon Lamb

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb today retired from the board following his announcement at the ASM that he would be stepping down once a new independent director had been appointed. This is in conjunction with today’s appointment of Andrew Lane to the Board.
Chair David Flacks said: “On behalf of the Board I would like to extend my thanks to Jon for his outstanding service during his 11-year tenure. His deep industry knowledge and experience has enabled him to make a significant contribution to the growth and success of AFT, and it has been a privilege to work alongside him.”

Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.


For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals (ASX:AFP, NZX:AFT)
www.aftpharm.com
AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter, prescription, and hospital. AFT Pharmaceutical's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs.




Announcement PDF


Markets News

Pushpay investors ponder takeover as NZX50 marches on
Markets The close

Pushpay investors ponder takeover as NZX50 marches on

Yield stocks such as Chorus and property investors led the market higher. 

Matt Martel 13 Nov 2022
Markets

Paul McBeth: Building a property portfolio with Winton

Here's a way the Sharesies generation can get their fill of property.

Paul McBeth 03 Dec 2021
Building a property portfolio with Winton
Markets

Morningstar picks Spark as omicron refuge

Spark’s share price spiked more than 5% early this week as investors reacted to news of the variant, but it had been trending down, sliding more than 10% in the past three months.

Dan Brunskill 02 Dec 2021
Morningstar picks Spark as omicron refuge